FDA
-
-
-
-
-
-
-
Candel Therapeutics launches phase 3 lung cancer trial for CAN-2409
-
-
-
-
-
-
-
Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial
-
-
-
-
-
-
-
Candel Therapeutics partners with EVERSANA for drug commercialization
-
-
-
-
-
-
-
Candel Therapeutics to present prostate cancer trial data at AUA meeting
-
-
-
-
-
-
-
Candel Therapeutics Announces Proposed $100 Million Public Offering
-
-
-
-
-
-
-
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

